Regeneron Pharmaceuticals Investor Presentation — June 2021

Document content

R e g e n e r o n G e n e t i c s M e d i c i n e s

B u i l d i n g t h e P i p e l i n e o f t h e F u t u r eJ U N E 2 9 , 2 0 2 1

R e g e n e r o n P h a r m a c e u t i c a l s , I n c .Note Regarding Forward -Looking Statements

2This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.

(“Regeneron” orthe“Company”), andactual events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,”

“believe,” “seek,” “estimate,” variations ofsuch words, and similar expressions areintended toidentify such forward -looking statements, although notallforward -looking

statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -CoV-2(thevirus thathas

caused theCOVID -19pandemic) onRegeneron’s business anditsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron’s andits

collaborators’ ability tocontinue toconduct research andclinical programs, Regeneron’s ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise

commercialized byRegeneron and/or itscollaborators (collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic

applications ofRegeneron’s Products and product candidates being developed byRegeneron and/or itscollaborators (collectively, “Regeneron’s Product Candidates”) and

research and clinical programs now underway orplanned, including Regeneron’s Product Candidates discussed inthispresentation (such asitepekimab ,cemdisiran and

pozelimab ,andNTLA -2001 )andtheuseofhuman genetics inRegeneron’s research ;safety issues resulting from theadministration ofRegeneron’s Products andRegeneron’s

Product Candidates inpatients, including serious complications orside effects inconnection withtheuseofRegeneron’s Products andRegeneron’s Product Candidates inclinical

trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial launch ofRegeneron’s Product Candidates andnew indications forRegeneron’s Products ;

thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch anddevelopment programs

conducted byRegeneron and/or itscollaborators (including those discussed inthispresentation) may bereplicated inother studies and/or lead toadvancement ofproduct

candidates toclinical trials, therapeutic applications, orregulatory approval ;ongoing regulatory obligations andoversight impacting Regeneron’s Products, research andclinical